Annals On Call - The Good, the Bad, and the Ugly—the Sequel: GLP1 Agonists
Authors: Robert M. Centor, Katherine R. Tuttle
Journal: Annals of Internal Medicine (2020)

Web Exclusives4 February 2020Annals On Call - The Good, the Bad, and the Ugly—the Sequel: GLP1 AgonistsFREERobert M. Centor, MD and Katherine R. Tuttle, MDRobert M. Centor, MDHuntsville Regional Medical Campus, University of Alabama Birmingham School of Medicine, Birmingham, Alabama (R.M.C.)Search for more papers by this author and Katherine R. Tuttle, MDProvidence Health Care and University of Washington School of Medicine, Spokane, Washington (K.R.T.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/A19-0023 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In this episode of Annals On Call, Dr. Centor discusses the role of glucagon-like peptide-1 receptor agonists in the treatment of patients with type 2 diabetes with Dr. Tuttle of Providence Health Care and University of Washington School of Medicine.Annals articles discussed include...In the Clinic. Type 2 Diabetes: https://annals.org/aim/fullarticle/2754207/type-2-diabetesBenefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments. A Systematic Review and Network Meta-analysis: https://annals.org/aim/fullarticle/2474362/benefits-harms-once-weekly-glucagon-like-peptide-1-receptor-agonistAbout Annals On CallAnnals On Call focuses on a clinically influential article published in Annals of Internal Medicine. Dr. Robert Centor shares his own perspective on the material and interviews topic area experts to discuss, debate, and share diverse insights about patient care and health care delivery.For more information on Annals On Call and for more episodes, visit go.annals.org/OnCall. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Huntsville Regional Medical Campus, University of Alabama Birmingham School of Medicine, Birmingham, Alabama (R.M.C.)Providence Health Care and University of Washington School of Medicine, Spokane, Washington (K.R.T.)Disclosures: Dr. Centor has disclosed the following: Honoraria: Medscape. Dr. Tuttle has disclosed the following: Honoraria: Eli Lilly and Company, AstraZeneca, Bayer. Consultantship: Eli Lilly and Company, AstraZeneca, Boehringer Ingelheim, Gilead, Goldfinch Bio, Novo Nordisk.Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that her spouse has stock options/holdings with Targeted Diagnostics and Therapeutics. Darren B. Taichman, MD, PhD, Executive Editor, reports that he has no financial relationships or interests to disclose. Cynthia D. Mulrow, MD, MSc, Senior Deputy Editor, reports that she has no relationships or interests to disclose. Jaya K. Rao, MD, MHS, Deputy Editor, reports that she has stock holdings/options in Eli Lilly and Pfizer. Christina C. Wee, MD, MPH, Deputy Editor, reports employment with Beth Israel Deaconess Medical Center. Sankey V. Williams, MD, Deputy Editor, reports that he has no financial relationships or interests to disclose. Yu-Xiao Yang, MD, MSCE, Deputy Editor, reports that he has no financial relationships or interest to disclose. Previousarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoBenefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments Francesco Zaccardi , Zin Zin Htike , David R. Webb , Kamlesh Khunti , and Melanie J. Davies Type 2 Diabetes Sandeep Vijan Metrics 4 February 2020Volume 172, Issue 3Page: OC1KeywordsDiagnostic techniquesDisclosureHealth careNetwork analysisPatientsSystematic reviewsType 2 diabetes ePublished: 4 February 2020 Issue Published: 4 February 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.Loading ...